B-cell lymphoma : nature.com subject feedshttps://www.nature.com/subjects/b-cell-lymphoma.atom2024-03-29T12:09:16+00:00Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphomahttps://www.nature.com/articles/s41375-024-02227-52024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Lin-Rui Gao et al.B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progressionhttps://www.nature.com/articles/s41598-024-55728-92024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Simona Gambino et al.Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMThttps://www.nature.com/articles/s41409-024-02256-92024-03-19T00:00:00+00:002024-03-19T00:00:00+00:00Romain Guièze et al.In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancieshttps://www.nature.com/articles/s41408-024-01036-42024-03-15T00:00:00+00:002024-03-15T00:00:00+00:00Zhiqiang Song et al.Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphomahttps://www.nature.com/articles/s41467-024-46220-z2024-03-08T00:00:00+00:002024-03-08T00:00:00+00:00Min Liu et al.Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyhttps://www.nature.com/articles/s41375-024-02213-x2024-03-08T00:00:00+00:002024-03-08T00:00:00+00:00Annalisa Chiappella et al.Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphomahttps://www.nature.com/articles/s41408-024-01022-w2024-03-07T00:00:00+00:002024-03-07T00:00:00+00:00Kylie Keijzer et al.The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphomahttps://www.nature.com/articles/s41375-024-02207-92024-03-07T00:00:00+00:002024-03-07T00:00:00+00:00Hildo C. Lantermans et al.Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based datasethttps://www.nature.com/articles/s41416-024-02629-32024-02-29T00:00:00+00:002024-02-29T00:00:00+00:00Mark P. Little et al.Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemiahttps://www.nature.com/articles/s41375-024-02162-52024-02-26T00:00:00+00:002024-02-26T00:00:00+00:00Ruth de Tute et al.Circulating tumor cells in Waldenström macroglobulinemiahttps://www.nature.com/articles/s41375-024-02156-32024-02-09T00:00:00+00:002024-02-09T00:00:00+00:00Clémentine Boccon-Gibod et al.Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomashttps://www.nature.com/articles/s41408-024-00997-w2024-02-08T00:00:00+00:002024-02-08T00:00:00+00:00Asaad Trabolsi et al.Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspectivehttps://www.nature.com/articles/s41409-024-02228-z2024-02-06T00:00:00+00:002024-02-06T00:00:00+00:00P. Ahmadi et al.Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectiveshttps://www.nature.com/articles/s41408-024-00989-w2024-01-25T00:00:00+00:002024-01-25T00:00:00+00:00Iman Abou Dalle et al.Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphomahttps://www.nature.com/articles/s41591-023-02754-12024-01-17T00:00:00+00:002024-01-17T00:00:00+00:00Frederick L. Locke et al.Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomahttps://www.nature.com/articles/s41375-023-02133-22024-01-10T00:00:00+00:002024-01-10T00:00:00+00:00Georg Lenz et al.Correction: Mechanisms of ferroptosis and targeted therapeutic approaches in lymphomahttps://www.nature.com/articles/s41419-023-06393-92024-01-09T00:00:00+00:002024-01-09T00:00:00+00:00Tiantian Yu et al.Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid modelhttps://www.nature.com/articles/s41419-023-06299-62024-01-09T00:00:00+00:002024-01-09T00:00:00+00:00Matthew R. Sullivan et al.Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphomahttps://www.nature.com/articles/s41375-023-02130-52024-01-09T00:00:00+00:002024-01-09T00:00:00+00:00Bangdong Liu et al.Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphomahttps://www.nature.com/articles/s41421-023-00625-02024-01-09T00:00:00+00:002024-01-09T00:00:00+00:00Wen Lei et al.Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialhttps://www.nature.com/articles/s41375-023-02134-12024-01-06T00:00:00+00:002024-01-06T00:00:00+00:00Chunye Zhang et al.Human leukocyte antigen-DQA1*04:01 and rs2040406 variants are associated with elevated risk of childhood Burkitt lymphomahttps://www.nature.com/articles/s42003-023-05701-52024-01-05T00:00:00+00:002024-01-05T00:00:00+00:00Zhiwei Liu et al.A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphomahttps://www.nature.com/articles/s41408-023-00971-y2024-01-04T00:00:00+00:002024-01-04T00:00:00+00:00A. V. de Jonge et al.Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlandshttps://www.nature.com/articles/s41408-023-00970-z2024-01-04T00:00:00+00:002024-01-04T00:00:00+00:00Elise R. A. Pennings et al.Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidshttps://www.nature.com/articles/s41409-023-02169-z2024-01-04T00:00:00+00:002024-01-04T00:00:00+00:00Olalekan O. Oluwole et al.Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysishttps://www.nature.com/articles/s41408-023-00967-82023-12-19T00:00:00+00:002023-12-19T00:00:00+00:00Marie-France Gagnon et al.Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphomahttps://www.nature.com/articles/s41409-023-02156-42023-12-15T00:00:00+00:002023-12-15T00:00:00+00:00Koji Kato et al.The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphomahttps://www.nature.com/articles/s41408-023-00958-92023-12-14T00:00:00+00:002023-12-14T00:00:00+00:00Jinrong Zhao et al.Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialhttps://www.nature.com/articles/s41591-023-02726-52023-12-10T00:00:00+00:002023-12-10T00:00:00+00:00Lihua E. Budde et al.Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialhttps://www.nature.com/articles/s41591-023-02722-92023-12-09T00:00:00+00:002023-12-09T00:00:00+00:00Othman Al-Sawaf et al.